IE 11 is not supported. For an optimal experience visit our site on another browser.

Zogenix to Present at 2011 Wells Fargo Securities Healthcare Conference

/ Source: GlobeNewswire

SAN DIEGO, June 13, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that Chief Executive Officer Roger L. Hawley will present an overview of the Company at the 2011 Wells Fargo Securities Healthcare Conference on June 22, 2011, at The InterContinental Hotel in Boston, MA.

Mr. Hawley and Ann Rhoads, Executive Vice President and Chief Financial Officer, will be available to respond to questions and to participate in one-on-one meetings with investors attending the conference.

The presentation will be Web cast live and archived for 90 days on Zogenix' Investor Relations Web site at ir.zogenix.com.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 with its co-promotion partner, Astellas Pharma US, Inc., for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZX002 is a novel, oral, single-entity extended-release formulation of hydrocodone currently in Phase 3 clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy.

For additional information, please visit .

SUMAVEL(R) and DosePro(R) are registered trademarks of Zogenix, Inc.

CONTACT: INVESTORS: Zack Kubow | The Ruth Group 646.536.7020 | zkubow@theruthgroup.com MEDIA: Jason Rando | The Ruth Group 646.536.7025 | jrando@theruthgroup.com